Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_assertion type Assertion NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_head.
- NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_assertion description "[We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_provenance.
- NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_assertion evidence source_evidence_literature NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_provenance.
- NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_assertion SIO_000772 18344568 NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_provenance.
- NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_assertion wasDerivedFrom befree-20140225 NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_provenance.
- NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_assertion wasGeneratedBy ECO_0000203 NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_provenance.